慢性乙型病毒性肝炎 PEG-IFNα 再治疗疗效的临床观察
摘要
（PEG-IFN-α-2b）的疗效差异。方法：回顾性纳入 HBsAg ＜ 10000 IU/ml 且 HBeAg 阴性的 CHB 患者 50 例，分为初
治组（26 例）和再治组（24 例），分析两组基线及治疗过程中 HBsAg、HBV DNA 的变化。结果：初治组基线 HBsAg 中
位数（1115.78 IU/ml）及 HBV DNA（3.93±1.18 log10IU/ml）均显著高于再治组（156.10 IU/ml，P=0.0072；2.83±1.02
log10IU/ml，P=0.0213）。治疗 12 周及 24 周时，两组 HBsAg 下降值、下降百分比及 HBV DNA 下降值均无统计学差异。
结论：既往 IFN-α 治疗的 HBeAg 阴性 CHB 患者在停药后仍可维持长期免疫控制及病毒学应答，其再次使用 PEG-IFN-
α-2b 的疗效与初治患者相当，且安全性良好，不良反应可控，耐受性高。
关键词
全文:
PDF镜像
|参考
[1] 尤红 , 王福生 , 李太生 , 孙亚朦 , 徐小元 , 贾继东 , 南
月敏 , 王贵强 , 侯金林 , 魏来 , 段钟平 , and 庄辉 , 慢性乙型
肝炎防治指南 (2022 年版 ). 实用肝脏病杂志 , 2023. 26(03): p.
457-478
[2] Sarin, S.K., M. Kumar, G.K. Lau, Z. Abbas, H.L. Chan,
C.J. Chen, D.S. Chen, H.L. Chen,P.J. Chen, R.N. Chien, A.K.
Dokmeci, E. Gane, J.L. Hou, W. Jafri, J. Jia, J.H. Kim, C.L. Lai,
H.C. Lee, S.G. Lim, C.J. Liu, S. Locarnini, M. Al Mahtab, R.
Mohamed, M. Omata, J. Park, T. Piratvisuth, B.C. Sharma, J.
Sollano, F.S. Wang, L. Wei, M.F. Yuen, S.S. Zheng, and J.H. Kao,
Asian-Pacific clinical practice guidelines on the management of
hepatitis B: a 2015 update. Hepatol Int, 2016. 10(1): p. 1-98.
[3] 中华医学会肝病学分会 , 扩大慢性乙型肝炎抗病毒
治疗的专家意见 中华肝脏病杂志 ,2022. 30(2): p. 131-136.
[4] Boni, C., D. Laccabue, P. Lampertico, T. Giuberti, M.
Viganò, S. Schivazappa, A. Alfieri, M. Pesci, G.B. Gaeta, G.
Brancaccio, M. Colombo, G. Missale, and C. Ferrari, Restored
function of HBV-specific T cells after long-term effective therapy
with nucleos(t)ide analogues. Gastroenterology, 2012. 143(4): p.
963-73.e9.
[5] Gan, W., N. Gao, L. Gu, Z. Mo, X. Pang, Z. Lei, and Z.
Gao, Reduction in Intrahepatic cccDNA and Integration of HBV in
Chronic Hepatitis B Patients with a Functional Cure. J Clin Transl
Hepatol, 2023. 11(2): p. 314-322.
[6] Ren, H. and Y. Huang, Effects of pegylated interferon-α
based therapies on functional cure and the risk of hepatocellular
carcinoma development in patients with chronic hepatitis B. J
Viral Hepat, 2019. 26 Suppl 1: p. 5-31.
[7] Nishio, A., F.J. Bolte, K. Takeda, N. Park, Z.X. Yu, H.
Park, K. Valdez, M.G. Ghany, and B. Rehermann, Clearance of
pegylated interferon by Kupffer cells limits NK cell activation and
therapy response of patients with HBV infection. Sci Transl Med,
2021. 13(587).
[8] Jiang, P., H. Jia, X. Qian, T. Tang, Y. Han, Z. Zhang, L.
Jiang, Z. Yu, L. Zheng, G. Yu, H. Cai, S. Zhang, X. Zhang, J. Gu,
C. Ye, L. Yang, Y. Lu, H. Liu, X. Lu, C. Jin, Y. Ren, M. Lu, L. Xu,
J. Yu, X. Jin, Y. Yang, and P. Qian, Single-cell RNA sequencing
reveals the immunoregulatory roles of PegIFN-α in patients with
chronic hepatitis B. Hepatology, 2024. 79(1): p. 167-182.
[9] Jeng, W.J. and A.S. Lok, Should Treatment Indications
for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol,
2021. 19(10): p. 2006-2014.
[10]Wong,G.L.H., E. Gane, and A.S.F. Lok, How to achieve
functional cure of HBV: Stopping NUCs, adding interferon or new
drug development? J Hepatol, 2022. 76(6): p. 1249-1262.
[11] Bi, X., S. Xie, S. Wu, W. Cao, Y. Lin, L. Yang, T. Jiang,
W. Deng, S. Wang, R. Liu, Y. Gao, G. Shen, M. Chang, H. Hao, M.
Xu, X. Chen, L. Hu, Y. Lu, L. Zhang, Y. Xie, and M. Li, Changes
of natural killer cells’ phenotype in patients with chronic
hepatitis B in intermittent interferon therapy. Front Immunol,
2023. 14: p. 1116689.
[12] Yang, X, K. Zhang, Q. Xu, X. Shu, Z. Mo, D. Xie, Z.
Gao, and H. Deng, Interferon add-on therapy increased clinical
cure significantly for interferon-experienced chronic hepatitis B
patients with low HBsAg. Front Immunol, 2022. 13: p. 997608.
[13] Yin, G.Q., K.P. Chen, and X.C. Gu, Heterogeneity of
immune control in chronic hepatitis B virus infection: Clinical
implications on immunity with interferon-α treatment and
retreatment. World J Gastroenterol, 2022. 28(40): p. 5784-5800.
[14] Zhang, M., M. Wan, W. Wang, S. Lin, and X. Zhang,
Effect of interferon therapy on quality of life in patients with
chronic hepatitis B. Sci Rep, 2024. 14(1): p. 2461.
(8 摘要 Views, 2 PDF Downloads)
Refbacks
- 当前没有refback。